Phaseline

Targets › ASXL3

ASXL3 (Putative Polycomb group protein ASXL3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout May 2027.

Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. (UniProt, Q9C0F0)

Open in Phaseline: the race on ASXL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
n-Lorem FoundationnL-ASXL3-001
Antisense oligonucleotide targeting ASXL3 nonsense variant
ASXL3Phase 1Bainbridge-Ropers SyndromeMay 2027

Conditions

Bainbridge-Ropers Syndrome (1)

Modalities

small molecule (1)

Companies

n-Lorem Foundation (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.